Onxeo shows good pre-clinical results for cancer combo
French-Danish biotech company Onxeo has presented good pre-clinical data for the combination of two of its cancer drugs, one of which is developed by Danish Topotarget, on various tumor cell lines. The company has filed a patent application for the possible combination treatment.
BY MARTIN HAVTORN PETERSEN
While the French-Danish biotech company Onxeo recently failed miserably in a phase III study of a liver cancer candidate, the company is now attempting to bounce back by presenting promising results for a combination of two other cancer drugs. This is according to a press release from Onxeo.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Onxeo raises EUR 15m in stock offering
For abonnenter
Onxeo cleared to continue liver cancer study
For abonnenter
